Are you a biotech scientist ready to file an EB-1A petition without seeing your strongest discoveries blocked by trade-secret restrictions or team-science attribution challenges? This course is the complete roadmap built specifically for drug discovery scientists, clinical trial leaders, gene therapy researchers, and senior biotech R&D executives across academia and industry.

Most biotech professionals actually have stronger EB-1A evidence than they realize — high-impact publications, IND and NDA submissions, ClinicalTrials.gov leadership roles, patent portfolios with commercial licensing, NIH grant histories, and FDA-approved therapies — but struggle with proprietary restrictions, multi-year drug development timelines, and isolating individual contributions from team-based discoveries. Generic immigration guides routinely miss what makes biotech cases win or fail at adjudication.

This course covers every component of a biotech EB-1A petition under one roof: all 10 criteria with drug-development-specific framing, the final merits standard that follows the 3-of-10 threshold, comparable evidence pathways for trade-secret-protected work, recommendation letter strategy tuned to biotech principal investigators and industry executives, and RFE-prevention thinking calibrated to life sciences scrutiny patterns.

Across 28 focused modules, you progress through four logical zones: a biotech-specific framework for selecting your strongest criteria, deep development across each of the 10 criteria with industry-specific evidence patterns from real cases, comparable evidence strategies for situations where regulatory filings or trade-secret-protected research replaces standard documentation, and the final merits and sustained acclaim analysis that ultimately decides approval. The course closes with a synthesis section covering recommendation letters, petition narrative integration, and the field-specific pitfalls that derail biotech EB-1A petitions year after year.

This course serves PhD-level research scientists at biotech companies and academic institutions, drug development leads managing IND and NDA submissions, clinical trial directors, bioinformatics specialists with computational methods, protein engineers, gene therapy researchers, agricultural biotech scientists, regulatory affairs professionals with scientific contributions, and senior R&D executives at firms like Genentech, Amgen, Moderna, Illumina, and CRISPR Therapeutics.

Grounded in 20 years of AAO decisions, USCIS policy guidance, and detailed analysis of approved biotech petitions from leading pharmaceutical companies and major research universities, this course distills what actually works in real life-sciences adjudications — not what generic immigration content suggests should work in theory. Every module reflects the patterns USCIS officers consistently accept from biotech professionals and the patterns they consistently reject.

Start today and transform your biotech career into a credible, evidence-backed EB-1A petition that holds up to the most rigorous USCIS scrutiny.

Are you a biotech scientist ready to file an EB-1A petition without seeing your strongest discoveries blocked by trade-secret restrictions or team-science attribution challenges? This course is the complete roadmap built specifically for drug discovery scientists, clinical trial leaders, gene therapy researchers, and senior biotech R&D executives across academia and industry.

Most biotech professionals actually have stronger EB-1A evidence than they realize — high-impact publications, IND and NDA submissions, ClinicalTrials.gov leadership roles, patent portfolios with commercial licensing, NIH grant histories, and FDA-approved therapies — but struggle with proprietary restrictions, multi-year drug development timelines, and isolating individual contributions from team-based discoveries. Generic immigration guides routinely miss what makes biotech cases win or fail at adjudication.

This course covers every component of a biotech EB-1A petition under one roof: all 10 criteria with drug-development-specific framing, the final merits standard that follows the 3-of-10 threshold, comparable evidence pathways for trade-secret-protected work, recommendation letter strategy tuned to biotech principal investigators and industry executives, and RFE-prevention thinking calibrated to life sciences scrutiny patterns.

Across 28 focused modules, you progress through four logical zones: a biotech-specific framework for selecting your strongest criteria, deep development across each of the 10 criteria with industry-specific evidence patterns from real cases, comparable evidence strategies for situations where regulatory filings or trade-secret-protected research replaces standard documentation, and the final merits and sustained acclaim analysis that ultimately decides approval. The course closes with a synthesis section covering recommendation letters, petition narrative integration, and the field-specific pitfalls that derail biotech EB-1A petitions year after year.

This course serves PhD-level research scientists at biotech companies and academic institutions, drug development leads managing IND and NDA submissions, clinical trial directors, bioinformatics specialists with computational methods, protein engineers, gene therapy researchers, agricultural biotech scientists, regulatory affairs professionals with scientific contributions, and senior R&D executives at firms like Genentech, Amgen, Moderna, Illumina, and CRISPR Therapeutics.

Grounded in 20 years of AAO decisions, USCIS policy guidance, and detailed analysis of approved biotech petitions from leading pharmaceutical companies and major research universities, this course distills what actually works in real life-sciences adjudications — not what generic immigration content suggests should work in theory. Every module reflects the patterns USCIS officers consistently accept from biotech professionals and the patterns they consistently reject.

Start today and transform your biotech career into a credible, evidence-backed EB-1A petition that holds up to the most rigorous USCIS scrutiny.